Literature DB >> 8268277

The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs.

S Pérez Gutthann1, L A García Rodríguez.   

Abstract

We conducted a nested case-control study to estimate and compare the relative risks for hospitalizations for newly diagnosed acute liver injury associated with the use of non-steroidal antiinflammatory drugs (NSAIDs) and other hepatotoxic drugs and their interaction. The source population comprised 228,392 members of the Saskatchewan Health Plan from 1982 to 1986. We used hospital records and the databases of the Department of Health. Thirty-four cases with confirmed liver injury were hospitalized. We randomly selected 500 controls from the source population. Crude risks ranged from 1 case per 100,000 prescriptions in current users of methyldopa, ampicillin, or NSAIDs to 14 cases per 100,000 prescriptions in current users of erythromycin estolate. The age-adjusted odds ratios for current users of NSAIDs was 1.8 [95% confidence interval (CI) = 0.8-3.7] and for other hepatotoxic drugs 5.9 (95% CI = 2.8-12.4). The adjusted relative excess risk due to the interaction between current exposure to both categories of drugs was 3.6, accounting for 31% of the cases of acute liver injury among those with exposure to both types of drugs. We conclude that the risk of hospitalization for acute noninfectious liver injury is different among users of various individual potentially hepatotoxic drugs. Concomitant current exposure to two or more drugs increases this risk above what would merely be expected from the sum of the individual risks.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8268277

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  13 in total

1.  Incidence of drug-induced liver injury in medical inpatients.

Authors:  Yvonne Meier; Marzia Cavallaro; Malgorzata Roos; Christiane Pauli-Magnus; Gerd Folkers; Peter J Meier; Karin Fattinger
Journal:  Eur J Clin Pharmacol       Date:  2005-02-23       Impact factor: 2.953

Review 2.  Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage?

Authors:  Fernando Bessone
Journal:  World J Gastroenterol       Date:  2010-12-07       Impact factor: 5.742

Review 3.  Safety profile of the fluoroquinolones: focus on levofloxacin.

Authors:  Hans H Liu
Journal:  Drug Saf       Date:  2010-05-01       Impact factor: 5.606

Review 4.  Hepatotoxicity related to antirheumatic drugs.

Authors:  Guruprasad P Aithal
Journal:  Nat Rev Rheumatol       Date:  2011-01-25       Impact factor: 20.543

Review 5.  Nonsteroidal anti-inflammatory drug-induced hepatic disorders. Incidence and prevention.

Authors:  A V Manoukian; J L Carson
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

6.  Assessment of case definitions for identifying acute liver injury in large observational databases.

Authors:  Aaron J Katz; Patrick B Ryan; Judith A Racoosin; Paul E Stang
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

7.  Acute and clinically relevant drug-induced liver injury: a population based case-control study.

Authors:  Francisco J de Abajo; Dolores Montero; Mariano Madurga; Luis A García Rodríguez
Journal:  Br J Clin Pharmacol       Date:  2004-07       Impact factor: 4.335

Review 8.  Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes.

Authors:  Françoise Van Bambeke; Paul M Tulkens
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

9.  Risk of acute liver injury associated with the use of moxifloxacin and other oral antimicrobials: a retrospective, population-based cohort study.

Authors:  James A Kaye; Jordi Castellsague; Christine L Bui; Brian Calingaert; Lisa J McQuay; Nuria Riera-Guardia; Catherine W Saltus; Scott Quinlan; Crystal N Holick; Peter M Wahl; Kiliana Suzart; Kenneth J Rothman; Mari-Ann Wallander; Susana Perez-Gutthann
Journal:  Pharmacotherapy       Date:  2013-11-05       Impact factor: 4.705

10.  Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system.

Authors:  J J Gagne; R J Glynn; J A Rassen; A M Walker; G W Daniel; G Sridhar; S Schneeweiss
Journal:  Clin Pharmacol Ther       Date:  2012-05-16       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.